Table 2. Distribution of KIR genes and KIR genotypes in patients with and without ocular toxoplasmosis and its primary or recurrent manifestations.
| Genes | Patients without ocular toxoplasmosis (n = 149) | Patients with ocular toxoplasmosis (n = 148) | Patients with primary manifestation (n = 120) | Patients with recurrent manifestation (n = 28) |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| KIR2DL1 | 149 (100) | 146 (98.6) | 118 (98.3) | 28 (100) |
| KIR2DL2 | 95 (63.8) | 101 (68.2) | 75 (62.5) | 23 (82.1) |
| KIR2DL3 | 131 (87.9) | 128 (86.5) | 102 (85.0) | 26 (92.9) |
| KIR2DL4 | 149 (100) | 148 (100) | 120 (100) | 28 (100) |
| KIR2DL5 | 85 (57.0) | 93 (62.8) | 70 (58.3) | 23 (82.1) |
| KIR2DP1 | 149 (100) | 146 (98.6) | 118 (98.3) | 28 (100) |
| KIR2DS1 | 63 (42.3) | 66 (44.6) | 51 (42.5) | 15 (53.6) |
| KIR2DS2 | 40 (26.8)a | 25 (16.9)a | 20 (16.6) | 5 (17.9) |
| KIR2DS3 | 54 (36.2) | 58 (39.2) | 42 (35.0) | 16 (57.1) |
| KIR2DS4 | 144 (96.6) | 141 (95.2) | 113 (94.2) | 28 (100) |
| KIR2DS5 | 56 (37.6) | 62 (41.9) | 49 (40.8) | 13 (46.4) |
| KIR3DL1 | 143 (96.0) | 145 (98.0) | 117 (97.5) | 28 (100) |
| KIR3DL2 | 149 (100) | 148 (100) | 120 (100) | 28 (100) |
| KIR3DL3 | 149 (100) | 148 (100) | 120 (100) | 28 (100) |
| KIR3DP1 | 149 (100) | 148 (100) | 120 (100) | 28 (100) |
| KIR3DS1 | 39 (26.1)b,c | 64 (43.2)b | 49 (40.8) | 15 (53.6)c |
| Genotypes | ||||
| AA | 41 (27.5) | 33 (22.3) | 27 (22.5) | 6 (21.4) |
| BX | 108 (72.4) | 115 (77.7) | 93 (80.0) | 22 (78.5) |
aOR = 0.55; CI = 0.31–0.97; P = 0.05; Pc = 0.80 (Patients without ocular toxoplasmosis vs. Patients with ocular toxoplasmosis).
bOR = 2.15; CI = 1.31–3.50; P = 0.003, Pc = 0.04 (Patients without ocular toxoplasmosis vs. Patients with ocular toxoplasmosis).
cOR = 3.25; CI = 1.42–7.44, P = 0.007; Pc = 0.1 (Patients without ocular toxoplasmosis vs. Patients with recurrent manifestation).